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Figure 1

pH-Sensitive Mucoadhesive Film-Forming Gels
Composition of Gel:
' A solvent vehicle comprising at least 25% water

I; I; A

- Water-insoluble swellable mucoadhesive polymer(s)
- pH-sensitive ?lm-forming polymer(s)
~ Molecule of interest

pH-Sensitive Mucoadhesive Wax-Film Composites

Composition of Wax-Film Composite:

A*:

pH-sensitive mucoadhesive layer (comprised of the
components of A above less the solvent vehicle)

B:

Water-insoluble wax layer with water-soluble or water

swellable polymer
Note: Molecule of interest is contained in either A* or B, or both
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Figure 2

ln-Vitro Adhesion Time of Wax-Film

Composites on Glass
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Figure 3

ln-Vitro Adhesion Time of Wax-Film Composites on
Glass
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Figure 4

in-Vitro Adhesion Time of Wax-Film

Composites Containing Plasmid DNA
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Figure 5
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Figure 6
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Figure 7
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Figure 8
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Figure 9
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PH-SENSITIVE MUCOADHESIVE
FILM-FORMING GELS AND WAX-FILM
COMPOSITES SUITABLE FOR TOPICAL
AND MUCOSAL DELIVERY OF MOLECULES

the Suzuki patent does not teach the use of pH-sensitive
wax-?lm composites intended to remain adhered to the skin
or mucosal surface for a prolonged period of time.
US. Pat. No. 5,800,832 by Tapolsky et al. relates to a

water-soluble, bioerodable device for the delivery of drugs,
and speci?cally dyclonine, to mucosal surfaces. The device

This application is a divisional of, and claims a bene?t of

priority under 35 U.S.C. § 120 from, application Ser. No.

comprises an adhesive layer as well as a non-adhesive layer.

09/748,133 ?led Dec. 27, 2000 now US. Pat. No. 7,803,392.

Both the adhesive layer and the nonadhesive layer consist of
water-soluble polymers such as cellulose-based polymers.
The Tapolsky patent does not teach the use of ?lm-forming

FIELD OF THE INVENTION

gels comprised of pH-sensitive polymers and water-insoluble
mucoadhesive polymers that form ?lms due to changes in pH
and/or desolvation of the polymers. Further, the Tapolsky

The present invention relates to compositions and methods
to treat the skin and mucosal surfaces with mucoadhesive

patent does not teach the use of pH-sensitive wax-?lm com
posites intended to remain adhered to the skin or mucosal

?lm-forming gels and wax-?lm composites that are pH-sen
sitive. The invention also relates to using such pH-sensitive
?lm-forming gels and wax-?lm composites to deliver mol
ecules of interest, namely active pharmaceuticals. The inven

surface for a prolonged period of time.

tion also relates to the use of said pH-sensitive ?lm-forming

gels and wax-?lm composites to deliver molecules of interest,
such as small molecules, peptides, proteins, and nucleic acids

20

either locally to act at the site of administration or for the

absorption of said molecules of interest across biological
membranes into the systemic circulation.
BACKGROUND OF THE INVENTION

25

US. Pat. No. 5,955,097 by Tapolsky et al. relates to a non
water-soluble gel, which adheres to mucosal surfaces and
body tissues upon application and forms a ?lm. The gel com
prises at least one water-insoluble cellulose-based polymer, a
non-aqueous solvent, and at least one active pharmaceutical.
The patent teaches that upon application to the mucosal sur

face or skin, the non-aqueous solvent, primarily ethanol,
evaporates, diffuses, or penetrates the surrounding tissue,
resulting in precipitation of the non water-soluble polymers
into ?lms. The Tapolsky patent further teaches the use of 50 to

Pharmaceutical formulations intended to deliver drugs
topically, either for local action at the site of administration or

80% ethanol by weight in the pharmaceutical gel. The Tapol

for absorption into the systemic circulation, have been

taining at least 25% water by weight and comprised of pH
sensitive polymers and water-insoluble mucoadhesive

described in the literature. These formulations are designed
either for adherence of the dosage form to the skin (for dermal

sky patent does not teach the use of ?lm-forming gels con
30

polymers that form ?lms due to changes in pH and/ or desol

vation of the polymers. Further, the Tapolsky patent does not

or transderrnal delivery of drugs) or mucosal surface (for
mucosal or transmucosal delivery of drugs). For skin delivery,
formulations generally consist of dermal patches, pastes,
band-aids, gels, lotions, sprays, or creams. For mucosal deliv

teach the use of pH-sensitive wax-?lm composites intended
to remain adhered to the skin or mucosal surface for a pro
35

ery, formulations generally consist of gels, creams, tablets,

US. Pat. No. 5,780,045 by McQuinn et al. relates to a
transmucosal drug delivery device in the form of a sheet

sprays, or ?lms. In either case, one speci?c requirement is that
the dosage form remains at the administration site for a suf
?cient amount of time so that the drug may function as

needed. A second speci?c requirement is that the dosage form
must consist of pharmaceutically acceptable materials. Many
of the reported and commercially available delivery systems
intended for topical and mucosal delivery are aqueous-based

comprising an acid-containing particulate polymer dispersed
40

formulations comprising water-soluble excipients. However,
these systems tend to be easily and quickly washed away from
the application site within minutes after application. This is
very undesirable if the drug must remain at the application

45

attempt to prolong the residence time at the application site,
50

to remain adhered to the skin or mucosal surface for a pro

US. Pat. No. 4,552,751 by Inaba et al. relates to the prepa
ration of multi-layered ?lms of three, ?ve, or seven layers for
the administration of speci?c prostaglandins to mucosal sites.
The Inaba patent does not teach the use of ?lm-forming gels

comprised of pH-sensitive polymers and water-insoluble
mucoadhesive polymers that form ?lms due to changes in pH
and/or desolvation of the polymers. Further, the Inaba patent
does not teach the use of pH-sensitive wax-?lm composites
55

Different types of formulations to deliver drugs topically
are known in the art. Speci?c examples are illustrated below.
US. Pat. No. 4,715,369 by Suzuki et al. relates to methods
to treat the injured oral mucosa with a thin two-layer tablet
comprised of both an adhesive layer and a nonadhesive layer.

in a polytetra?uoroethylene support matrix. The McQuinn
patent does not teach the use of ?lm-forming gels comprised
of pH-sensitive polymers and water-insoluble mucoadhesive
polymers that form ?lms due to changes in pH and/ or desol
vation of the polymers. Further, the McQuinn patent does not
teach the use of pH-sensitive wax-?lm composites intended

longed period of time.

site for a prolonged period in order to be ef?cacious. In an

researchers have described the use of water-insoluble excipi
ents in the formulations. However, most often the use of
water-insoluble excipients necessitates the use of non-aque
ous solvents to dissolve the excipients. Excessive and
repeated administration of non-aqueous solvents is not desir
able.

longed period of time.

intended to remain adhered to the skin or mucosal surface for

a prolonged period of time.
US. Pat. No. 4,517,173 by Kizawa et al. relates to a ?lm

60

preparation consisting of at least three layers, including a
pharmaceutical layer, a poorly water-soluble layer, and an
intermediate layer. The pharmaceutical layer consists of pre

The adhesive layer is comprised of water-soluble cellulose
based polymers and polyacrylic acid while the nonadhesive
layer is comprised mostly of materials with no adhesive prop

lose-based polymer. The poorly water-soluble layer consists

erties. The Suzuki patent does not teach the use of ?lm

the use of ?lm-forming gels comprised of pH-sensitive poly

forming gels comprised of pH-sensitive polymers and water

donisolone and allantoin together with a water-soluble cellu

of shellack or fatty acids. The Kizawa patent does not teach
65

mers and water-insoluble mucoadhesive polymers that form

insoluble mucoadhesive polymers that form ?lms due to

?lms due to changes in pH and/or desolvation of the poly

changes in pH and/or desolvation of the polymers. Further,

mers. Further, the Kizawa patent does not teach the use of

US 8,865,150 B2
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pH-sensitive wax-?lm composites intended to remain

at least one pH-sensitive ?lm-forming polymer, and

adhered to the skin or mucosal surface for a prolonged period
of time.
U.S. Pat. No. 5,192,802 by Rencher describes the use of a

The solvent vehicle may be comprised of at least 25 to 100
parts water or buffered water with 0 to 75 parts of ethanol,

bioadhesive teething gel comprising benzocaine, sodium car
boxy methyl cellulose; an agent selected from the group

tions thereof. The water-insoluble swellable mucoadhesive

at least one molecule of interest.

propylene glycol, glycerin, polyethylene glycol, or combina

consisting of xanthan gum and sodium alginate and a diluent

polymer may be polyacrylic acid cross-linked with polyalk
enyl ether or divinyl glycol, wherein the water-insoluble

selected from the group consisting of polyethylene glycol and
polyethylene glycol with glycerine. U.S. Pat. No. 5,314,915
by Rencher and Us. Pat. No. 5,298,258 by Akemi et al. also

swellable mucoadhesive polymer is preferably, Noveon or
Carbomer. The water-insoluble swellable mucoadhesive
polymer may be present at a concentration of from 0.1% to

describe the use of aqueous or oil-based bioadhesive gelling

agents. These patents do not teach the use of ?lm-forming

20% by weight.

gels comprised of pH-sensitive polymers and water-insoluble

The pH-sensitive polymer is a copolymer of methacrylic

mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, these patents do

acid and acrylic or methacrylic ester. Preferably, it is present

20

at a concentration of from 0.05% to 10% by weight. More
preferably, the polymer is a Eudragit polymer, or a chemical
derivative thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina
tion thereof. Preferably, the molecule of interest is amlex

25

anox, triclosan, peptide, protein, hirudin, plasmid DNA,

not teach the use of pH-sensitive wax-?lm composites
intended to remain adhered to the skin or mucosal surface for

a prolonged period of time.
U.S. Pat. Nos. 5,081,157 and 5,081,158 by PomerantZ
relate to a ?lm-forming composition for topical application of

medicaments to body tissues. The ?lm-forming composition
includes hydroxypropyl cellulose, a volatile solvent, and an
esteri?cation agent which reacts with the hydroxypropyl cel
lulose to form a reaction product which is soluble in the
solvent. These patents do not teach the use of ?lm-forming

gels comprised of pH-sensitive polymers and water-insoluble

lidocaine, benzocaine, dyclonine, or benzodiazepine drug or

mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, these patents do

a derivative thereof.

not teach the use of pH-sensitive wax-?lm composites

which when applied to the skin or mucosal surface forms a

The invention is also directed to a pharmaceutical gel

intended to remain adhered to the skin or mucosal surface for

30

a prolonged period of time.
U.S. Pat. No. 4,900,554 by Yanagibashi et al. relate to the
use of a device for the delivery of drugs in the oral cavity. The
device comprises an adhesive layer consisting of at least one
acrylic acid polymer, a water-insoluble cellulose derivative,

?lm, said gel comprising a solvent vehicle, at least one water
insoluble swellable mucoadhesive polymer, at least one pH
sensitive ?lm-forming polymer, and at least one molecule of
interest, wherein said ?lm is formed due to changes in pH and

35

for the delivery of the molecule of interest to or through the
application site. The solvent vehicle may be comprised of at
least 25 to 100 parts water with 0 to 75 parts of ethanol,

desolvation of the polymer, and wherein said ?lm provides

and a pharmaceutical preparation, and a water-insoluble or

sparingly soluble backing layer. Yanagibashi et al. state that
“it is impossible to achieve an adhesive device for application

propylene glycol, glycerin, polyethylene glycol, or combina

to body tissue without all three components, that is, acrylic

tions thereof. The water-insoluble swellable mucoadhesive

acid polymer, water insoluble cellulose derivative and water

40

insoluble or sparingly soluble backing layer”. The
Yanagibashi patent does not teach the use of ?lm-forming

swellable mucoadhesive polymer is Noveon or Carbomer.

gels comprised of pH-sensitive polymers and water-insoluble
mucoadhesive polymers that form ?lms due to changes in pH
and/ or desolvation of the polymers. Further, the Yanagibashi

45

patent does not teach the use of pH-sensitive wax-?lm com
posites intended to remain adhered to the skin or mucosal

surface for a prolonged period of time.
As illustrated, the references described above appear to
lack preferred compositions and properties for an ef?cacious

50

and pharmaceutically acceptable bioadhesive delivery sys
tem. Namely, the references do not describe primarily aque

ous-based ?lm-forming gels comprised of pH-sensitive poly
55

lidocaine, benzocaine, dyclonine, or benzodiazepine drug or
60

SUMMARY OF THE INVENTION

a derivative thereof. The application site may be the skin,
mouth, vagina, nose, nasal cavity, or other accessible mucosal
site.
The invention is also directed to a wax-?lm composite
comprised of a pH-sensitive mucoadhesive layer and a water

insoluble wax layer. The pH-sensitive mucoadhesive layer

The invention is directed to a pharmaceutical gel compo

sition comprising:
mer,

tion thereof. Preferably, the molecule of interest is amlex

anox, triclosan, peptide, protein, hirudin, plasmid DNA,

mers. Further, the references do not describe pH-sensitive
mucoadhesive wax-?lm composites intended to remain
adhered to the skin or mucosal surface for a prolonged period
of time.

a solvent vehicle,
at least one water-insoluble swellable mucoadhesive poly

The water-insoluble swellable mucoadhesive polymer may
be present at a concentration of from 0.1% to 20% by weight.
The pH-sensitive polymer may be a copolymer of meth
acrylic acid and acrylic or methacrylic ester. Preferably, it is
present at a concentration of from 0.05% to 10% by weight.
More preferably, the polymer is a Eudragit polymer, or a
chemical derivative thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina

mers and water-insoluble mucoadhesive polymers that form

?lms due to changes in pH and/or desolvation of the poly

polymer may be polyacrylic acid cross-linked with polyalk
enyl ether or divinyl glycol. Preferably, the water-insoluble

may be present at a concentration of 20% to 90% by weight,
65

and the water-insoluble wax layer may be present at a con

centration of 10% to 80% by weight. The pH-sensitive
mucoadhesive water-insoluble layer may be comprised of:

US 8,865,150 B2
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(i) adding a mucoadhesive polymer to a stirring water to
form a solution that is clear and viscous,

at least one water-insoluble swellable mucoadhesive poly
mer,

(ii) adding the pH-sensitive ?lm-forming polymer to the

at least one pH-sensitive ?lm-forming polymer, and

solution formed in step (i) and measuring the pH of the

at least one molecule of interest.

The water-insoluble swellable mucoadhesive polymer is
polyacrylic acid cross-linked with polyalkenyl ether or divi

01

(iii) adding the molecule of interest to the solution of step

(ii), and
(iv) forming the ?nal gel composition.

nyl glycol. Preferably, the water-insoluble swellable mucoad
hesive polymer is Noveon or Carbomer.

The invention is also directed to a method of making the

The pH-sensitive polymer may be a copolymer of meth
acrylic acid and acrylic or methacrylic ester. More preferably,

above wax-?lm composite, comprising:
(i) forming a homogeneous mucoadhesive ?lm by fusing a
mucoadhesive polymer and a pH-sensitive ?lm-forming

the polymer is a Eudragit polymer, or a chemical derivative
thereof.
The molecule of interest may comprise an active pharma
ceutical such as an antimicrobial, antiviral, antiin?ammatory,
antiseptic, antihistamine, a local anesthetic, a disinfectant, a
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a
sweetener, a ?avoring agent, a diagnostic agent, or combina
tion thereof. Preferably, the molecule of interest is amlex

anox, triclosan, hirudin, plasmid DNA, lidocaine, ben

solution,

polymer,
(ii) homogeneously coating one side of the mucoadhesive

20

?lm of step (i) with a melted wax composition, and
(iii) drying the wax composition to form the wax-?lm
composite, wherein the molecule of interest is added in
either step (i) or (ii), or the molecule of interest is added
to the mucoadhesive side after the wax-?lm composite is
formed.

zocaine, dyclonine, or benzodiazepine drug or a derivative
thereof. The wax-?lm composite may comprise at least one

Furthermore, the invention is also directed to a method of
treating a disease or an illness by administering to a person in

water-insoluble pharmaceutical wax having a melting point

need thereof, the gel or the wax-?lm composite as described
above comprising a molecule of interest.

between 40° C. and 100° C. and at least one water-soluble or

water-swellable polymer.

25

BRIEF DESCRIPTION OF THE DRAWINGS

The wax may be DENTSPLY® Utility Wax, beeswax,
emulsifying wax, microcrystalline wax, carnauba wax, par
a?in wax, white wax, yellow wax, or other suitable pharma

The present invention will become more fully understood

from the detailed description given hereinbelow, and the
accompanying drawings which are given by way of illustra

ceutical wax. The water-soluble or swellable polymer may be
present in the insoluble wax layer at a concentration of 0.05 to

tion only, and thus are not limitative of the present invention,

10% by weight. The water-soluble or swellable polymer may

and wherein;

be tragacanth, polyvinyl pyrrolidone, polyvinyl alcohol,
cross-linked polyacrylic acid, polyethylene glycol, a cellu
lose polymer derivative, or other suitable pharmaceutical

35

polymer that is water-soluble or water-swellable. In the wax

composites (n:3 each) on glass submerged in 40 mM
KHZPO4/NaOH buffer, pH 6 at 37° C. (unstirred). Each

?lm composite, the molecule of interest may be contained in
and released from either the pH-sensitive mucoadhesive layer
or the water-insoluble wax layer.

The molecule of interest comprises an active pharmaceu
tical compound such as an antimicrobial, antiviral, antiin
?ammatory, antiseptic, antihistamine, a local anesthetic, a
disinfectant, a keratolytic, an analgesic, an anti-migraine, an
anti-fungal, a sweetener, a ?avoring agent, a diagnostic agent,

40

or a combination thereof. The molecule of interest may com

45

anesthetic, a disinfectant, a keratolytic, an analgesic, an anti
migraine, an anti-fungal, a sweetener, a ?avoring agent, a
50

Each mucoadhesive layer contains from 1.2 mg to 11.2 mg of
total polymer comprised of Noveon and Eudragit S100 in a
weight ratio of 3:1. The wax layer consists of DENTSPLY®

Utility Wax containing 1% w/w tragacanth polymer. See

ecule of interest is amlexanox, triclosan, protein, peptide,
hirudin, plasmid DNA, lidocaine, benzocaine, dyclonine, or

Table 2 and Example 9 for additional details.
FIG. 4 shows in vitro adhesion time of 1A inch wax-?lm

benzodiazepine drug or a derivative thereof. Preferably, the
hirudin may be complexed with a substance of opposite

composites containing plasmid DNA (10 pg) either incorpo
rated during the manufacturing process (‘preload’) or ali
quoted onto the mucoadhesive layer after the manufacturing

charge. More preferably, the substance of opposite charge
may be chitosan or protamine. Alternatively, the molecule of
interest may be a plasmid DNA or plasmid DNA complexed
with a substance of opposite charge such as chitosan, prota

The application site for the wax-?lm composite may be the
skin, mouth, vagina, nasal cavity, or other accessible mucosal
site. Preferably, the wax-?lm composite adheres to the appli

in Example 8. See Table 1 and Example 8 for additional
details.
FIG. 3 shows in vitro adhesion time of 1A inch wax-?lm

composites (n:3 each) on glass submerged in 40 mM
KH2PO4/NaOH buffer, pH 6 at 37° C. (stirred at 100 rpms).

viral, antiin?ammatory, antiseptic, antihistamine, a local

mine, or a cationic lipid.

mucoadhesive layer contains 5.0-5.3 mg of total polymer
comprised of Noveon and Eudragit S100 in the ratios indi
cated. The wax layer consists of DENTSPLY® Utility Wax
containing 1% w/w tragacanth polymer. *Indicates that dif
ferent volumes of mucoadhesive gels were cast as described

prise an active pharmaceutical such as an antimicrobial, anti

diagnostic agent, or combination thereof. Preferably, the mol

FIG. 1 shows a summary of the compositions of the inven
tion
FIG. 2 shows an in vitro adhesion time of 1A inch wax-?lm

process (‘postload’). Wax-?lm composites (n:5 each) were
adhered to glass and submerged in 40 mM KHZPO4/NaOH
buffer, pH 6 at 37° C. (unstirred). See Example 10 for addi
OO

tional details.
FIG. 5 shows a standard curve forplasmid DNA in solution

as measured by the PicoGreen DNA Quantitation Kit (from

Molecular Probes, Inc., Eugene, Oreg.).
FIG. 6 shows the release of plasmid DNA pre-loaded into

cation site for at least 1 hour. Preferably, the wax-?lm com
posite has a total thickness of less than 5 mm.
The invention is also directed to a method of making the

wax-?lm composites. Wax-?lm composites were made as
described in Example 10 using a mucoadhesive gel com

above pharmaceutical gel composition, comprising:

prised of Noveon/Eudragit S100 (3:1 w/w) and plasmid

US 8,865,150 B2
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DNA. The wax layer consists of DENTSPLY® Utility Wax
containing 1% w/w tragacanth polymer. Five 1A inch wax

?lm composites containing of plasmid DNA (5 pg) were

least one water-insoluble swellable mucoadhesive polymer,
at least one pH-sensitive ?lm-forming polymer, and at least
one molecule of interest, said ?lm forming due to changes in

submerged separately into 1 mL 10 mM PBS buffer, pH 7.4 at
370 C. At various times, exactly 100 ML solution was ali

pH and desolvation of the polymer, said ?lm providing for the
delivery of the molecule of interest to or through the applica

quoted for DNA quantitation using the PicoGreen DNA

tion site.
The pH-sensitive mucoadhesive wax-?lm composite is a
bi-layer pharmaceutical ?lm less than 5 mm in diameter that
when applied to the skin or mucosal surface adheres to the
application for at least 1 hour. The wax-?lm composite is
comprised of a pH-sensitive mucoadhesive layer and a water
insoluble wax layer.

Quantitation Kit. Exactly 100 ML fresh PBS was added to
replace the removed volume at each time point.
FIG. 7 shows the release of plasmid DNA post-loaded into
wax-?lm composites. Wax-?lm composites were made as
described in Example 10 using a mucoadhesive gel com

prised of Noveon/Eudragit S100 (3:1 w/w). The wax layer
consists of DENTSPLY® Utility Wax containing 1% w/w
tragacanth polymer. Plasmid DNA (5 pg) was added to ?ve
individual 1A inch wax-?lm composites, allowed to air dry for
4 hours, and then submerged separately into 1 mL 10 mM
PBS buffer, pH 7.4 at 370 C. At various times, exactly 100 ML
solution was aliquoted for DNA quantitation using the
PicoGreen DNA Quantitation Kit. Exactly 100 ML fresh PBS
was added to replace the removed volume at each time point.

De?nitions and Preferred Embodiments

As used herein, certain terms may have the following

de?ned meanings.
As used in the speci?cations and claims, the singular form
a, an and the include plural references unless the context
20

the presently disclosed formulations and methods.

TH and uncomplexed thrombin. Hirudin was added to excess

The term molecule of interest is de?ned as any synthetic or

thrombin and residual uncomplexed thrombin was assayed

naturally occurring substance including elements, radioac

spectroscopically after the addition of Chromozym-TH.
Hirudin was added to the 1.0 ml volume in the following

25

The term active pharmaceutical means any synthetic or

naturally occurring substance including elements, radioac
tive elements, synthetic or natural small molecules, peptides,

difference between the thrombin base value absorbance
30

times and the average AUC was plotted.
FIG. 10 shows the Particle Size of Hirudin/Chitosan Com
plexes in water made with hirudin at a Concentration of 0.5

pharmacological response. The terms pharmaceutical, active
pharmaceutical, and drug as used herein are identical in
35
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otide, or plasmid DNA, or any derivative or combinations
thereof.
Amlexanox: The chemical name of Amlexanox is

b]-pyridine-3-carboxylic acid. Amlexanox is the active ingre
dient in the commercial product, Aphthasol, which acceler
ates the healing of aphthous ulcers in the mouth by an
unknown mechanism (Binnie et al. 1997; Khandwala et al.
1997a; Khandwala et al. 1997b). The Aphthasol product is a
5% paste. In cell culture experiments, Amlexanox has been
shown to inhibit the formation or release of in?ammatory

Chitosan complexes in water was diluted in 900 ML ethanol to

determine the stability of the complexes in ethanol.
DETAILED DESCRIPTION OF THE INVENTION
55

mediators such as histamine and leukotrienes from mast cells,

60

neutrophils, and mononuclear cells (Urisu et al. 1990). Eur
ther, in animals, Amlexanox has anti-allergic and anti-in?am
matory properties and has been shown to inhibit both imme
diate and delayed hypersensitivity reactions (Saijo et al.
1985; Saijo et al. 1986). Amlexanox has very poor solubility

The invention relates to delivery systems suitable for the

topical and mucosal delivery of molecules of interest. Spe
ci?cally, the invention relates to; 1) compositions of pH
sensitive mucoadhesive ?lm-forming gels, 2) uses of pH

sensitive mucoadhesive ?lm-forming gels, 3) compositions

monoclonal antibody, polyclonal antibody, nucleic acid, or
combinations thereof. More preferably, the active pharma
ceutical is amlexanox, triclosan, lidocaine, dyclonine, ben
zocaine, a benzodiazepine, hirudin, antisense oligonucle

2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3

FIG. 12 shows the stability of Hirudin/Chitosan Com
plexes (4:1 w/w) made in water as function of Hirudin con
centration and storage time. All samples were stored at 4° C.

For the Day 7 sample analysis, exactly 100 ML of Hirudin/

meaning and thus are used interchangeably. It is preferred that
the active pharmaceutical be an anti-microbial, antiviral, anti

in?ammatory, antiseptic, antihistamine, tranquilizer, seda
tive, anti-nausea, local anesthetic, disinfectant, keratolytic,
analgesics including anti-migraine, anti-fungal, sweetener,
?avoring agent, diagnostic agent, peptide, protein, antigen,

mg/mL.
FIG. 11 shows the Zeta Potential of Hirudin/Chitosan
Complexes in water made with Hirudin at a Concentration of
0.1 mg/mL. Zeta Potential values are reported as the mean
and standard deviation of three measurements.

proteins, nucleic acids, or any combinations thereof intended
to be administered to a warm-blooded mammal to elicit a

sample values versus the concentration of hirudin standards
from A.
FIG. 9 shows an HPLC Standard Curve for Hirudin. Three
standard curves for hirudin were generated using a C18

Nucleosil® 5 pm analytical column (4.6><250 mm). The
mobile phase consisted of water:acetonitrile:tri?uoroacetic
acid (59.95:40:0.05 w/w/w). The ?ow rate was 0.6 mL/min.
Each 50 ML sample of each standard curve was injected three

tive elements, synthetic or natural small molecules, peptides,
proteins, nucleic acids, or any combinations thereof.

amounts: 0 ng (III), 16.9 ng (C), 33.8 ng (A), 50.7 ng (A), 67.6
ng (0), and 84.4 ng (I). (B) Calibration curve for released
hirudin in solution. The ?gure was made by plotting the
(thrombin in the presence of substrate only) and the hirudin

clearly dictates otherwise. For example, the term a pharma
ceutical may refer to one or more pharmaceuticals for use in

FIG. 8 shows: (A) The reaction kinetics of Chromozym

of pH-sensitive mucoadhesive wax-?lm composites, and 4)

in ethanol (0.58 mg/mL) and water (0.005 mg/mL). However,

uses of pH-sensitive mucoadhesive wax-?lm composites. A
summary of the compositions of the invention is shown in

the solubility of Amlexanox increases with pH.

FIG. 1.

Trichloro 2'-hydroxy-diphenylether 5-chloro 2-(2,4-dichlo

The pH-sensitive mucoadhesive ?lm-forming gel is a phar
maceutical gel which when applied to the skin or mucosal
surface forms a ?lm, said gel comprising a solvent vehicle, at

Triclosan: The chemical name of Triclosan is 2,4,4'
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rophenoxy)-phenol. Triclosan is a broad-spectrum antibacte
rial that has activity against a wide range of gram-positive and

gram-negative bacteria (Zuckerbraun et al. 1998). Triclosan

US 8,865,150 B2
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has been shown to inhibit bacterial fatty acid synthesis at the

muscle relaxation. In turn, benzodiazepines are used for the
treatment of seizures and insomnia, preoperative or proce
dural sedation, and for the treatment of nausea and anxiety.
Most if not all of the benzodiazepine bases have little or no
solubility in water and are very lipophilic (Hjortkjaer et al.
1999, Bechgaard et al. 1997). As a result, a great deal of

enoyl-acyl carrier protein reductase (FabI) step (Heath et al.
1999). It has gained wide-spread use as antibacterial agent
that is used in toothpastes, kitchen utensils and toys. Triclosan
has also been formulated in mouthwashes (Mandel 1994) and
liposomes (Jones et al 1993). Triclosan has a pKa of7.9 and
is insoluble in water, except in alkaline solutions where it is

research has gone into developing ef?cacious dosage forms

readily soluble (Loftsson et al. 1999). However, triclosan is
soluble in ethanol and polyethylene glycol 400 and many
other organic solvents.

of these drugs including; i) synthesizing water-soluble
derivatives such as their hydrochloride salts, ii) developing
injectable formulations of the benzodiazepine bases that do
not result in precipitation of the drugs, and iii) exploring

Hirudin: Hirudin is the most potent and speci?c known

inhibitor of thrombin (Kl-:02 pM) (Markwardt 1989; Mark
wardt 1991a; Markwardt 1991b; Fenton et al. 1991). Hirudin
was originally isolated from medicinal leeches (Hirudo
medicinalis), but is now available in large quantities due to
recombinant techniques (Riehl-Bellon et al. 1989). Unlike
heparin, hirudin does not require endogenous cofactors to
function and does not have associated bleeding complica
tions. Hirudin is a relatively small 65 amino acidpeptide (Mw
7000) with remarkable stability over a broad range of pH (pH
3-10), temperature (i.e., up to 60° C.), and solvent conditions
(Chang 1991; Eric and Caroline 1991). The main structure of

alternative routes of administration including intranasal, rec
tal, and buccal. Previous work has shown that intranasal doses

of the benzodiazepine bases dissolved in organic solvents
lead to pharmacological responses with suitable pharmaco
kinetic pro?les. However, the repeated use of organic solvents

such as ethanol, polyethylene glycol, and propylene glycol
for intranasal administration is not desirable. Alternatively,
20

al. 1999). For example, Schwagmeier et al. showed that the

hirudin is characterized by an apolar disul?de knot with a

very anionic (negatively-charged) tail. The apolar knot of
hirudin masks the catalytic site of thrombin by interacting

maximum plasma concentration of midazolam was 55.9
ng/mL at 30 minutes following buccal administration of 5 mg
25

with its apolar site (i.e., via hydrophobic interaction). The
anionic tail of hirudin (18 amino acids) interacts with the
anion-binding exosite of thrombin. It is the combination of
the apolar binding and the anion-binding that accounts for the
very high af?nity of hirudin and thrombin. The presence of

30

a means to safely and reproducibly deliver doses of the ben
35

remains extracellular (Fenton 1989). It is likely that the
anionic portion of hirudin is electrostatically repelled from
the surface of cell membranes. Novartis Pharma obtained
40

of deep-vein thrombosis following knee and hip replacement
surgery. In clinical trials, patients receiving hirudin by sub
45
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of hirudin require blood levels between 80 to 3500 ng/mL

(Markwardt 1989, Markwardt 1991). A potential problem
with the use of injected forms of hirudin is that there are no

effective antidotes for hirudin overdosing. If upon frequent
injection, the wrong dose is given, there are no methods to
turn the activity of hirudin off. For this reason alone, hirudin
is a good candidate for transmucosal delivery via the buccal
tissue. It is envisioned that the pH-sensitive mucoadhesive
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?lm-forming gel or wax-?lm composite containing hirudin,
can easily be applied to the buccal tissue in the mouth and
provide a means to safely control the dosing and dose sched

clonazepam, desmethyldiazepam, diazepam, ?unitrazepam,
?urazepam, halazepam, lorazepam, lormethazepam, mida
olam, and derivatives and combinations thereof.
The term pharmaceutically acceptable means that the sub
stance is generally regarded to be safe when used in such a
manner that is widely acceptable by those skilled in the art.
For reference of acceptable materials, refer to THE UNITED
STATES PHARMACOEPIA.
The term pH-sensitive is de?ned as a substance that is

use hirudin in acute coronary syndrome. Several other indi
cations for hirudin are being pursued such as stasis-induced
venous thrombosis, diffuse microthrombosis, and hemodi

alysis (Markwardt 1989). Most of the potential applications

zodiazepines for the treatment of seizures and insomnia, pre
operative or procedural sedation, and for the treatment of
nausea and anxiety. Benzodiazepines suitable for delivery
are, but not limited to, alprazolam, camazepam, clobazam,

zolam, nitrazepam, oxazepam, pinazepam, prazepam, triaz

cutaneous injection twice a day for 8 days had a nearly 30%
lower overall rate of deep-vein thrombosis than those who

received low molecular weight heparin (Eriksson et al. 1997).
Novartis is also performing clinical trials (Phase III) for the

native to injection or intranasal administration. It is envi

sioned that the said pH-sensitive mucoadhesive ?lm-forming
gel or wax-?lm composite containing a benzodiazepine can
easily be applied to the buccal tissue in the mouth and provide

hydrophobic and hydrophilic surface interactions. For
example, in solution, hirudin forms micellar complexes (e.g.,
tetramers) with itself. Further, the apolar region of hirudin is

marketing approval in the European Union in 1998 for
REVASC (desirudin; recombinant hirudin) for the prevention

midazolam with a mean bioavailability of 74.5%. Scott et al.

reported that the buccal administration of 10 mg midazolam
per 2 mL stopped 75% (30/40) seizures in children within an
average time of 6 minutes after administration. Thus, buccal
administration of benzodiazepines may be an attractive alter

the apolar knot and anionic tail on hirudin results in both

known to interact with cell membranes while the anionic tail

benzodiazepines have been given by buccal administration
with very favorable results (Schwagmeier et al. 1998; Scott et
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affected by changes in pH so that the substance changes
conformation, charge, solubility, or combinations thereof. A
pH-sensitive polymer is de?ned as polymer that is affected by
changes in pH so that the polymer changes conformation,
charge, solubility, or combinations thereof. A pH-sensitive
?lm-forming polymer is de?ned as polymer that is affected by
changes in pH so that the polymer changes conformation,
charge, solubility, or combinations thereof resulting in the
precipitation, desolvation, or settling of the polymer into a
?lm. For the purposes of this invention, it is preferred that the
pH-sensitive ?lm-forming polymers have some solubility in
aqueous-based vehicles above pH 5 but limited or no solubil

ity below pH 5. It is more preferred that the pH-sensitive
?lm-forming polymers have some solubility in aqueous

uling of hirudin.
Benzodiazepines: Benzodiazepines are among the most

based vehicles above pH 6 but limited or no solubility below

frequently prescribed drugs in the Western world. All benzo
diazepine agonists exert similar pharmacodynamic actions

pH 6. It is most preferred that the pH-sensitive ?lm-forming
polymers have some solubility in aqueous-based vehicles
above pH 7 but limited no solubility below pH 7. Examples of
pH-sensitive ?lm-forming polymers that meet these criteria

(e.g., activate central GABAergic neuroinhibition, thereby
inducing anxiolysis, sedation/hypnosis, anticonvulsion and
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